Literature DB >> 10494497

Patient satisfaction with, and acceptability of, atypical antipsychotics.

A Kalali.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10494497     DOI： 10.1185/03007999909113374

Source DB:  PubMed          Journal:  Curr Med Res Opin        ISSN： 0300-7995            Impact factor:   2.580


× No keyword cloud information.
  15 in total

1.  Who Receives Nalmefene and How Does It Work in the Real World? A Single-Arm, Phase IV Study of Nalmefene in Alcohol Dependent Outpatients: Baseline and 1-Month Results.

Authors:  Pablo Barrio; Lluisa Ortega; Josep Guardia; Carlos Roncero; Lara Yuguero; Antoni Gual
Journal:  Clin Drug Investig       Date:  2018-02       Impact factor: 2.859

2.  Use of quetiapine to manage patients who experienced adverse effects with clozapine.

Authors:  Michael J Reinstein; John G Sonnenberg; Sangarapillai C Mohan; Maxim A Chasanov; Lynne E Jones
Journal:  Clin Drug Investig       Date:  2003       Impact factor: 2.859

3.  Baseline Demographics and Characteristics From a Paliperidone Palmitate Study in Subjects with Recent-Onset Schizophrenia or Schizophreniform Disorder.

Authors:  Brianne Brown; Larry Alphs; Ibrahim Turkoz; Yong Yue
Journal:  Psychopharmacol Bull       Date:  2017-08-01

Review 4.  Quetiapine: a review of its safety in the management of schizophrenia.

Authors:  V Dev; J Raniwalla
Journal:  Drug Saf       Date:  2000-10       Impact factor: 5.606

Review 5.  Patients' subjective experiences of antipsychotics: clinical relevance.

Authors:  Jonathan S E Hellewell
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

6.  Reduction in psychotic symptoms as a predictor of patient satisfaction with antipsychotic medication in schizophrenia: data from a randomized double-blind trial.

Authors:  Georges M Gharabawi; Andrew Greenspan; Marcia F T Rupnow; Colette Kosik-Gonzalez; Cynthia A Bossie; Young Zhu; Amir H Kalali; A George Awad
Journal:  BMC Psychiatry       Date:  2006-10-20       Impact factor: 3.630

7.  Satisfaction of immediate or delayed switch to paliperidone palmitate in patients unsatisfied with current oral atypical antipsychotics.

Authors:  Jun Soo Kwon; Sung Nyun Kim; Jaewook Han; Sang Ick Lee; Jae Seung Chang; Jung-Seok Choi; Heon-Jeong Lee; Seong Jin Cho; Tae-Youn Jun; Seung-Hwan Lee; Changsu Han; Kyoung-Uk Lee; Kyung Kyu Lee; EunJung Lee
Journal:  Int Clin Psychopharmacol       Date:  2015-11       Impact factor: 1.659

8.  A 6-year open-label study of the efficacy and safety of olanzapine long-acting injection in patients with schizophrenia: a post hoc analysis based on the European label recommendation.

Authors:  Ernie Anand; Lovisa Berggren; Claudia Deix; Ágoston Tóth; David P McDonnell
Journal:  Neuropsychiatr Dis Treat       Date:  2015-05-27       Impact factor: 2.570

9.  Patient perspectives in the development and use of long-acting antipsychotics in schizophrenia: focus on olanzapine long-acting injection.

Authors:  Leslie Citrome
Journal:  Patient Prefer Adherence       Date:  2009-11-29       Impact factor: 2.711

Review 10.  Current approaches to treatments for schizophrenia spectrum disorders, part II: psychosocial interventions and patient-focused perspectives in psychiatric care.

Authors:  Wai Tong Chien; Sau Fong Leung; Frederick Kk Yeung; Wai Kit Wong
Journal:  Neuropsychiatr Dis Treat       Date:  2013-09-25       Impact factor: 2.570
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.